{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-003490","form_type":"8-K","ticker":"DMRA","cik":"0001800315","company_name":"Damora Therapeutics, Inc.","filed_at":"2026-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:36.215213+00:00","generated_at":"2026-05-16T11:33:02.282734+00:00","sec_items":["3.02","5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Galecto appoints Sherwin Sattarzadeh as COO; issues warrant to Paramora","bullets":["Sherwin Sattarzadeh appointed COO effective Jan 5, 2026; base salary $540,000, target bonus 40%.","Initial equity grant includes 190,376 RSUs and options for 444,209 shares vesting over four years.","Issued warrant to Paramora for 628,302 shares at $23.01 per share under Paragon Option Agreement.","Severance provisions: 12 months' salary (18 months if within Change in Control Period) plus accelerated vesting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-003490","json":"https://secwatch.observer/filing/0001193125-26-003490.json","markdown":"https://secwatch.observer/filing/0001193125-26-003490.md","text":"https://secwatch.observer/filing/0001193125-26-003490.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526003490/0001193125-26-003490-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800315/000119312526003490/glto-20251231.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T11:33:02.282734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}